Relationship between Preoperative 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Both 18F-fluorodeoxyglucose (18F-FDG) uptake and epidermal growth factor receptor (EGFR) status are prognostic variablesof colorectal cancer (CRC). The aim of this study was to investigate a possible association between 18F-FDG uptake on preoperativepositron emission tomography/computed tomography (PET/CT) and EGFR status in primary CRC. Materials and Methods: Records of 132 patients (66 men and 66 women; mean age=67.1±11.1 years) who underwent 18F-FDG PET/CT for CRC staging and subsequent bowel resection were reviewed. In primary lesions, 18F-FDG uptake was semiquantitativelyevaluated in terms of maximum standardized uptake value (SUVmax), and EGFR status was determined by immunohistochemistry. Associations of clinicopathological parameters and EGFR status were analyzed by Pearson’s chi-square test, multiple logistic regression, and receiver operating characteristic curves. Results: Eighty-six patients (65.2%) showed EGFR expression. SUVmax was significantly lower in EGFR-negative tumors than in EGFR-expressing tumors (10.0±4.2 vs. 12.1±2.1; p=0.012). It was the only significant parameter correlated with EGFR expression (odds ratio=2.457; relative risk=2.013; p=0.038). At the SUVmax threshold of 7.5, the sensitivity and specificity for predicting EGFR expression were 84.9% and 40.4%, respectively (area under the curve=0.624; p=0.019). Conclusion: Preoperative 18F-FDG uptake is slightly correlated with EGFR status in primary CRC. Preoperative SUVmax of 18F-FDG may have a limited role in predicting EGFR expression in such tumors because of its poor specificity.
Abstract
Purpose: Both 18F-fluorodeoxyglucose (18F-FDG) uptake and epidermal growth factor receptor (EGFR) status are prognostic variablesof colorectal cancer (CRC). The aim of this study was to investigate a possible association between 18F-FDG uptake on preoperativepositron emission tomography/computed tomography (PET/CT) and EGFR status in primary CRC. Materials and Methods: Records of 132 patients (66 men and 66 women; mean age=67.1±11.1 years) who underwent 18F-FDG PET/CT for CRC staging and subsequent bowel resection were reviewed. In primary lesions, 18F-FDG uptake was semiquantitativelyevaluated in terms of maximum standardized uptake value (SUVmax), and EGFR status was determined by immunohistochemistry. Associations of clinicopathological parameters and EGFR status were analyzed by Pearson’s chi-square test, multiple logistic regression, and receiver operating characteristic curves. Results: Eighty-six patients (65.2%) showed EGFR expression. SUVmax was significantly lower in EGFR-negative tumors than in EGFR-expressing tumors (10.0±4.2 vs. 12.1±2.1; p=0.012). It was the only significant parameter correlated with EGFR expression (odds ratio=2.457; relative risk=2.013; p=0.038). At the SUVmax threshold of 7.5, the sensitivity and specificity for predicting EGFR expression were 84.9% and 40.4%, respectively (area under the curve=0.624; p=0.019). Conclusion: Preoperative 18F-FDG uptake is slightly correlated with EGFR status in primary CRC. Preoperative SUVmax of 18F-FDG may have a limited role in predicting EGFR expression in such tumors because of its poor specificity.
참고문헌 (30)
- Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
- Iyer RB, "Imaging in the diagnosis, staging, and follow-up of colorectal cancer", AJR Am J Roentgenol, 179, pp.3~13 (2002)
- Filippone A, "Preoperative T and N staging of colorectal cancer: accuracy of contrast-enhanced multi-detector row CT colonography--initial experience", Radiology, 231, pp.83~90 (2004)
- Jemal A, "Cancer statistics, 2004", CA Cancer J Clin, 54, pp.8~29 (2004)
- Grizzle WE, "Molecular characterization of colorectal neoplasia in translational research", Arch Pathol Lab Med, 125, pp.91~98 (2001)
- Fearon ER, "Molecular genetics of colorectal cancer", Annu Rev Pathol, 6, pp.479~507 (2011)
- Yasui W, "Expression of epidermal growth factor receptor in human gastric and colonic carcinomas", Cancer Res, 48, pp.137~141 (1988)
- Cunningham D, "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer", N Engl J Med, 351, pp.337~345 (2004)
- Kopp R, "Clinical implications of the EGF receptor", ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options, 2003, pp.162, 115~132
- Mayer A, "The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer", Cancer, 71, pp.2454~2460 (1993)
- Goldstein NS, "Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system", Cancer, 92, pp.1331~1346 (2001)
- Park IJ, "Effcacy of PET", CT in the accurate evaluation of primary colorectal carcinoma, 2006, pp.32, 941~947
- Herbertson RA, "Established, emerging and future roles of PET", CT in the management of colorectal cancer, 2009, pp.64, 225~237
- Eun Kyoung Choi, "Value of Surveillance 18F-FDG PET", CT in Colorectal Cancer: Comparison with Conventional Imaging Studies, 2012, pp.46(3), 189~195[DOI]
- Gambhir SS, "A tabulated summary of the FDG PET literature", J Nucl Med, 42(5 Suppl), pp.1S~93S (2001)
- de Geus-Oei LF, "FDG-PET in colorectal cancer", Cancer Imaging, 6, pp.S71~S81 (2006)
- Kwon MJ, "Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances", Hum Pathol, 45, pp.1327~1338 (2014)
- Delbeke D, "PET and PET-CT for evaluation of colorectal carcinoma", Semin Nucl Med, 34, pp.209~223 (2004)
- Figueiras RG, "The role of functional imaging in colorectal cancer", AJR Am J Roentgenol, 195, pp.54~66 (2010)
- Kostakoglu L, "Clinical role of FDG PET in evaluation of cancer patients", Radiographics, 23, pp.315~340 (2003)
- Tatlidil R, "Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings", Radiology, 224, pp.783~787 (2002)
- Abdel-Nabi H, "Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings", Radiology, 206, pp.755~760 (1998)
- Mukai M, "Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer", Oncol Rep, 7, pp.85~87 (2000)
- Gu J, "Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer", Dig Dis Sci, 51, pp.2198~2205 (2006)
- 나세정, "원발성 대장-결장암 환자의 치료 전 PET", CT 스캔에서 FDG 섭취 정도와 병리학적 및 면역조직화학적 지표들과의 비교, 2009, pp.43(6), 557~564[DOI]
- Huang SM, "Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results", Invest New Drugs, 17, pp.259~269 (1999)
- Wu X, "Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin", J Clin Invest, 95, pp.1897~1905 (1995)
- Weihua Z, "Survival of cancer cells is maintained by EGFR independent of its kinase activity", Cancer Cell, 13, pp.385~393 (2008)
- Sinicrope FA, "Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes", Gastroenterology, 148, pp.88~99 (2015)
- Xu Q, "Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis", J Dig Dis, 14, pp.409~416 (2013)